Doug Holtzman

Company: ICOSAVAX

Job title: Chief Scientific Officer

Seminars:

A Novel Two-Component VLP Technology for the Development of Vaccines Against Respiratory Viruses 4:00 pm

Vaccine technology covering an RSV/hMPV bivalent vaccine as well as a SARS2 candidate which is in Ph1 testing now in Australia Advantages of computational protein design to better inform antigen formulation and to achieve higher efficacy ratesRead more

day: Pre-Conference Focus Day: Respiratory Infectious Disease Vaccine Development

A Novel Two-Component VLP Technology for the Development of Vaccines Against Respiratory Viruses 4:15 pm

Vaccine technology covering an RSV/hMPV bivalent vaccine as well as a SARS2 candidate which is in Ph1 testing now in Australia Advantages of computational protein design to better inform antigen formulation and to achieve higher efficacy ratesRead more

day: Day One Morning